TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Course duration of cured patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total dose of meperidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dihydroxyphenylglycol (DHPG) levels in CSF and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5-Hydroxytryptamine (5-HT) levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of itchiness
Endpoint domain: Adverse events/effects
Primary endpoint: Time for first exhaust after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum levels of sFas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteinized granulosa cell DNA fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: parent-proxy quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perineal pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality within 3 years after engraftment
Endpoint domain: Mortality/survival
Primary endpoint: Biopsy-confirmed rejection (BCAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and discomfort reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection-free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Average total cost of delivering antibiotic treatment
Endpoint domain: Resource use
Primary endpoint: Postural activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence of new myopia onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: axial growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum and mean bite forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-swallowing particle sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of chews and mastication time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in Z-scores for weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean change in Z-scores for head circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CIBIC-Plus scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to awaken from sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized Swallowing Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia Outcome Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing‐Related Quality of Life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lack of curve progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NIPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PIPP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H. pylori test‐ordering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proton pump inhibitor use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative recurrence rate of EVs
Endpoint domain: Mortality/survival
Primary endpoint: incidence of epigastralgia
Endpoint domain: Adverse events/effects
Primary endpoint: intraoperative BP and oxygen saturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Bone Mineral Content (BMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IL6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to bony union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival to transplantation
Endpoint domain: Mortality/survival
Primary endpoint: one-year survival rate after transplantation
Endpoint domain: Mortality/survival
Primary endpoint: five-year survival rate after transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of postoperative ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of Applied Rehabilitation Concepts measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disordered-eating attitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychiatric inventory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vulvovaginal mycotic infection
Endpoint domain: Adverse events/effects
Primary endpoint: successful outcome
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Ability to perform basic activities of daily living (bADLs)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: new or enlarging T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A&E department attendance
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Visits to general practitioner for problematic asthma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recall of informed consent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: EQ-5D VAS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Importance of video as a source of information about clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preparation to discuss the trial with physician
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family understanding of clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Intertherapist agreement on intrapelvic motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saturated fatty acid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Polyunsaturated fatty acid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean global arterial-phase vessel attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting and postprandial triacylglycerol (TAG) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apo B‐48 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial RE response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PSI changes correlated with motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cooperation skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Rate of asthma-related emergency visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vocabulary Comprehension Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocabulary Production Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver fat fraction (LFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Visual analogue scale (VAS) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in differentiation of small choroidal melanoma from pseudomelanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity in differentiation of small choroidal melanoma from pseudomelanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Exact agreement in differentiation of small choroidal melanoma from pseudomelanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alveolar interleukin 8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvement in laboratory parameters of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse effects attributable to minocycline
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Patient-Reported Outcomes (PROs)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in NAFLD Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hepatic collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAM-D-17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain grade reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of hyperplastic lump reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion achieving minimal physical activity recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of carrier screening tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Previously unrecognised carriership
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intraventricular hemorrhage (IVH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Substance use prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contractile activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: noncontractile patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: turbid intestinal content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hypoglycemia detection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in absenteeism due to infection
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: weight gain
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative stroke rate
Endpoint domain: Adverse events/effects
Primary endpoint: Overall perioperative complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Hallucination Change Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hallucination frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: straight-leg raise range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Combined response (HBeAg seroconversion plus HBV DNA <2000 IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: swelling improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory parameters improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to ramipril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in duration of rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of hospital resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CYP2A6 phenotyping ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in numeric rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of neurological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quantitative determination of vibration sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Deep-sternal infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of perioperative major stroke and death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of early carotid occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NHP energy scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: VAS for activity pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slight pain rate
Endpoint domain: Adverse events/effects
Primary endpoint: No edema rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dose area product fluoroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of severe hypocalcaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion to positivity for antibodies against KSHV-related nuclear antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: R0-resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of tumour rupture
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in MMSE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in immediate logical memory scores of WMS‐III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in delayed logical memory scores of WMS‐III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to discharge from hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in need for ongoing inhaled salbutamol therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identifying hemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disc size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glaucoma likelihood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in plaque thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in plaque area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sampling-induced blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: risk of inappropriate ICD therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of selenium and vitamin E supplements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: beta half-life of gentamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of distribution of gentamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance of gentamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of disruptive behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Responsiveness Scale (SRS)-2 completion rates
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Goal-based measure completion rates
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Time to achieve TOF ratios of 0.8 and 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration to spontaneous T1 25% recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery index (T1 from 25% to 75%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in tender and swollen joint counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of postoperative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cumulative morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in occurrence of nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Headache cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: free-of-rebleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in vitamin D insufficiency prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular redness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial spontaneous voiding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of post-void residual
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of late relapse
Endpoint domain: Mortality/survival
Primary endpoint: IGF‐1/IGFBP‐1 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IGFBP‐3 mean differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of infants alive and extubated at 48 hours
Endpoint domain: Mortality/survival
Primary endpoint: Duration of oxygen support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bronchopulmonary dysplasia among survivors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of STI services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Use of perinatal services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Use of antenatal services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Histological deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum uric acid (SUA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of children up to date with preventive services
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade I-II neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade III neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: UC-related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: UC- or drug-related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pap smear completion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the thickness of the authentic hybrid layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvement in clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ethmoid sinus inflammation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SNOT-20 score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in morning HBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute renal allograft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hemoglobin (Hgb) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of death from cardiovascular causes
Endpoint domain: Mortality/survival
Primary endpoint: Overall functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptive language
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Symmetry satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing